Epithelial-mesenchymal transition and its regulators are major targets of triple-negative breast cancer

Cell Adhesion and Migration

Volumn 7, Issue 5, 2013, Pages 424-425

  Al Moustafa, Ala Eddin ^a,b,c  

^a Dept of Electrical and Computer Engineering   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c Syrian Research Cancer Centre   (Syrian Arab Republic)

Author keywords

Breast cancer; c Met; EMT; IGF 1; Leptin; Metastasis cancer mortality; Triple negative

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; LEPTIN; MITOGEN ACTIVATED PROTEIN KINASE; SCATTER FACTOR RECEPTOR; SOMATOMEDIN; STAT3 PROTEIN;

CANCER CELL; CANCER GROWTH; CANCER MORTALITY; DIET RESTRICTION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; METASTASIS; ONCOGENE SRC; PHYSICAL ACTIVITY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; TRIPLE NEGATIVE BREAST CANCER; TUMOR INVASION;

BREAST CANCER; C-MET; EMT; IGF-1; LEPTIN; METASTASIS & CANCER MORTALITY; TRIPLE NEGATIVE;

CELL PROLIFERATION; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; LEPTIN; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROTO-ONCOGENE PROTEINS C-MET; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84891864612     PISSN: 19336918     EISSN: 19336926     Source Type: Journal    
DOI: 10.4161/cam.26728     Document Type: Review

References (20)

1. Zagouri F, Bago-Horvath Z, Rössler F, Brandstetter A, Bartsch R, Papadimitriou CA, Dimitrakakis C, Tsigginou A, Papaspyrou I, Giannos A, et al. High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer. Br J Cancer 2013; 108:1100-5; PMID:23422757; http://dx.doi.org/10.1038/bjc.2013.31
2. Nakopoulou L, Gakiopoulou H, Keramopoulos A, Giannopoulou I, Athanassiadou P, Mavrommatis J, Davaris PS. c-met tyrosine kinase receptor expression is associated with abnormal beta-catenin expression and favourable prognostic factors in invasive breast carcinoma. Histopathology 2000; 36:313-25; PMID:10759945; http://dx.doi.org/10.1046/j.1365-2559.2000.00847.x
3. Tolgay Ocal I, Dolled-Filhart M, D'Aquila TG, Camp RL, Rimm DL. Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors. Cancer 2003; 97:1841-8; PMID:12673709; http://dx.doi.org/10.1002/cncr.11335
4. Lengyel E, Prechtel D, Resau JH, Gauger K, Welk A, Lindemann K, Salanti G, Richter T, Knudsen B, Vande Woude GF, et al. C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int J Cancer 2005; 113:678-82; PMID:15455388; http://dx.doi.org/10.1002/ijc.20598
5. Al Moustafa AE, Achkhar A, Yasmeen A. EGF-receptor signaling and epithelial-mesenchymal transition in human carcinomas. [Schol Ed]. Front Biosci (Schol Ed) 2012; 4:671-84; PMID:22202084; http://dx.doi.org/10.2741/S292
6. Hung CM, Kuo DH, Chou CH, Su YC, Ho CT, Way TD. Osthole suppresses hepatocyte growth factor (HGF)-induced epithelial-mesenchymal transition via repression of the c-Met/Akt/mTOR pathway in human breast cancer cells. J Agric Food Chem 2011; 59:9683-90; PMID:21806057; http://dx.doi.org/10.1021/jf2021489
7. Sivakumar R, Koga H, Selvendiran K, Maeyama M, Ueno T, Sata M. Autocrine loop for IGF-I receptor signaling in SLUG-mediated epithelial-mesenchymal transition. Int J Oncol 2009; 34:329-38; PMID:19148466
8. Shirakihara T, Horiguchi K, Miyazawa K, Ehata S, Shibata T, Morita I, Miyazono K, Saitoh M. TGF-β regulates isoform switching of FGF receptors and epithelial-mesenchymal transition. EMBO J 2011; 30:783-95; PMID:21224849; http://dx.doi.org/10.1038/emboj.2010.351
9. Guarino M. Src signaling in cancer invasion. J Cell Physiol 2010; 223:14-26; PMID:20049846
10. Yan D, Avtanski D, Saxena NK, Sharma D. Leptin-induced epithelial-mesenchymal transition in breast cancer cells requires β-catenin activation via Akt/GSK3- and MTA1/Wnt1 protein-dependent pathways. J Biol Chem 2012; 287:8598-612; PMID:22270359; http://dx.doi.org/10.1074/jbc.M111.322800
11. Catalano S, Mauro L, Marsico S, Giordano C, Rizza P, Rago V, Montanaro D, Maggiolini M, Panno ML, Andó S. Leptin induces, via ERK1/ERK2 signal, functional activation of estrogen receptor alpha in MCF-7 cells. J Biol Chem 2004; 279:19908-15; PMID:14985328; http://dx.doi.org/10.1074/jbc.M313191200
12. Cirillo D, Rachiglio AM, la Montagna R, Giordano A, Normanno N. Leptin signaling in breast cancer: an overview. J Cell Biochem 2008; 105:956-64; PMID:18821585; http://dx.doi.org/10.1002/jcb.21911
13. Davis AA, Kaklamani VG. Metabolic syndrome and triple-negative breast cancer: a new paradigm. Int J Breast Cancer 2012; 2012:809291; PMID:22295251; http://dx.doi.org/10.1155/2012/809291
14. Spina A, Di Maiolo F, Esposito A, D'Auria R, Di Gesto D, Chiosi E, Sorvillo L, Naviglio S. Integrating leptin and cAMP signalling pathways in triple-negative breast cancer cells. [Landmark Ed]. Front Biosci (Landmark Ed) 2013; 18:133-44; PMID:23276914; http://dx.doi.org/10.2741/4092
15. Otvos L Jr., Kovalszky I, Riolfi M, Ferla R, Olah J, Sztodola A, Nama K, Molino A, Piubello Q, Wade JD, et al. Efficacy of a leptin receptor antagonist peptide in a mouse model of triple-negative breast cancer. Eur J Cancer 2011; 47:1578-84; PMID:21353530; http://dx.doi.org/10.1016/j.ejca.2011.01.018
16. Law JH, Habibi G, Hu K, Masoudi H, Wang MY, Stratford AL, Park E, Gee JM, Finlay P, Jones HE, et al. Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 2008; 68:10238-46; PMID:19074892; http://dx.doi.org/10. 1158/0008-5472.CAN-08-2755
17. Hursting SD, Lavigne JA, Berrigan D, Perkins SN, Barrett JC. Calorie restriction, aging, and cancer prevention: mechanisms of action and applicability to humans. Annu Rev Med 2003; 54:131-52; PMID:12525670; http://dx.doi.org/10.1146/annurev.med.54.101601.152156
18. Rock CL, Pande C, Flatt SW, Ying C, Pakiz B, Parker BA, Williams K, Bardwell WA, Heath DD, Nichols JF. Favorable changes in serum estrogens and other biologic factors after weight loss in breast cancer survivors who are overweight or obese. Clin Breast Cancer 2013; 13:188-95; PMID:23375717; http://dx.doi.org/10.1016/j.clbc.2012.12.002
19. Al Moustafa A. Fasting inhibits human cancer progression via the epithelial-mesenchymal transition process: Important evidence unraveled. Clin Cancer Investig J 2012; 1:181-3
20. Al Moustafa AE. Insulin-like growth factor-1 enhances mortality risk in women with breast cancer through epithelial-mesenchymal transition initiation. Clin Cancer Investig J 2013; 2:175-7